Experimental cancer pill targets Hard-to-Treat tumors
NCT ID NCT06560645
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tested an experimental oral drug called PRT7732 in people with advanced solid tumors that have a specific genetic mutation (SMARCA4). The main goals were to check safety, find the right dose, and see if the drug could shrink tumors. The study was terminated early, so results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PRT7732 (an oral drug that targets and degrades a protein called SMARCA2)
- What this could lead to
- If successful, this could point toward a new treatment option for people with certain advanced cancers that have a SMARCA4 mutation.
- What could go wrong
- This was a very early (Phase 1) trial with only 42 participants, and it was terminated, meaning results may be limited. The drug may not shrink tumors or may cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Border Medical Oncology Research Unit
Albury, New South Wales, 2640, Australia
-
Brigitte Harris Cancer Pavilion
Detroit, Michigan, 48202, United States
-
Cancer Institute Hospital of JFCR
Koto-ku, Tokyo, 135-8550, Japan
-
Hospital Universitario HM Sanchinarro
Madrid, 28050, Spain
-
Hospital Universitario Vall d'Hebron
Barcelona, 08035, Spain
-
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Kindai University Hospital
Sayama, Osaka, 589-8511, Japan
-
Linear Clinical Research Ltd
Nedlands, Western Australia, 6009, Australia
-
Memorial Sloan Kettering Cancer Center - Main Campus
New York, New York, 10065, United States
-
Monash Health
Clayton, Victoria, 3168, Australia
-
National Cancer Center
Goyang-si, Gyeonggi-do, 10408, South Korea
-
National Cancer Center Hospital
Chuo Ku, Tokyo, 104-0045, Japan
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
Samsung Medical Center
Seoul, 06351, South Korea
-
Scientia Clinical Research Ltd
Randwick, New South Wales, 2031, Australia
-
Severance Hospital, Yonsei University Health System
Seoul, 03722, South Korea
-
Southern Highlands Cancer Centre
Bowral, New South Wales, 2576, Australia
-
Start Madrid-FJD, Hospital Universitario Fundacion Jimenez Diaz-Servicio de Oncologia
Madrid, 28040, Spain
-
Technische Universitat Dresden, Medizinlsche Fakultat Carl Gustav Carus Nationales Centrum fur Tumorerkrankungen Dresden, Early Clinical Trial Unit (NCT/UCC ECTU)
Dresden, Saxony, 01307, Germany
-
The Univerity of Osaka Hospital
Suita, Osaka, 565-0871, Japan
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, 94158, United States
-
UNC Hospitals, The University of North Carolina Chapel Hill
Chapel Hill, North Carolina, 27514, United States
-
University Clinic Cologne, Clinic for Internal Medicine
Cologne, North Rhine-Westfalia, 50937, Germany
-
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
-
University of Virginia Comprehensive Cancer Center
Charlottesville, Virginia, 22903, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can your own immune cells beat advanced cancer?
- Can a targeted pill keep lung cancer from returning?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?